Two Trials to Evaluate TEV-53408 in Participants With Non-Segmental Vitiligo
- Study Title
- A Multicenter, Randomized, Double-Blind, Placebo-Controlled Program Consisting of a Phase 2b Trial and a Phase 3 Trial to Evaluate the Efficacy and Safety of TEV-53408 in Participants With Non-Segmental Vitiligo
- Teva Identifier
- TV53408-IMM-30105
- ClinicalTrials.gov Identifier
- NCT07920211
- Study Status
- Not yet recruiting
- Trial Condition(s)
- Vitiligo
- Interventions
- Drug: TEV-53408|Drug: Placebo
- EU CT Number
- 2026-527760-32-00
- Study Description
- Please refer to ClinicalTrials.gov for a description of the trial
Key Participation Requirements
- Gender
- Female, Male
- Age group
- Adult, Older Adult
- Age Range
- 18 Years and older
- Trial Duration
- November 16, 2026 - June 19, 2031
- Phase
- Phase 2/3